prostate cancer

Test predicts PCSM at 10 years post prostatectomyNew research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
HIFU results in low morbidity, QoL preservationAnother study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.
How cutting carbs may benefit men on hormonal therapyRecent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.
Prostate Ca phenotypic assay predicts adverse clinical pathologyIn this interview, Dr. David Albala sits down to discuss his award-winning poster on live-cell phenotypic biomarkers at the 2016 AUA with Urology Times Editorial Consultant, Dr. J. Brantley Thrasher.
Are you seeing more advanced prostate Ca in your practice?Three urologists give their take on the frequency of patients presenting with prostate cancer.
The return of prostate cancer: A step backwardUrologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.
Prostate Ca: Novel model predicts ‘true cancer state’Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.
Slow breathing technique helps reduce hot flashesA slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.
QoL prognostic in mCRPC patients on salvage therapyClinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Negative mpMRI does not rule out significant PCaAs interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.